These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 14719194

  • 1. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

  • 2. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
    Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, De Portu S, Carrabba M, Bianchi Porro G.
    Aliment Pharmacol Ther; 2005 Sep 01; 22(5):453-61. PubMed ID: 16128684
    [Abstract] [Full Text] [Related]

  • 3. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar 01; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 4. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar 01; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 5. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 01; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 6. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.
    Haraoui B, Cameron L, Ouellet M, White B.
    J Rheumatol; 2006 Jan 01; 33(1):31-6. PubMed ID: 16395747
    [Abstract] [Full Text] [Related]

  • 7. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M, Creemers MC, Welsing PM, van Riel PL.
    Rheumatology (Oxford); 2005 Apr 01; 44(4):472-8. PubMed ID: 15598707
    [Abstract] [Full Text] [Related]

  • 8. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul 01; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 9. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study.
    van den Bemt BJ, den Broeder AA, Snijders GF, Hekster YA, van Riel PL, Benraad B, Wolbink GJ, van den Hoogen FH.
    Ann Rheum Dis; 2008 Dec 01; 67(12):1697-701. PubMed ID: 18245109
    [Abstract] [Full Text] [Related]

  • 10. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis.
    Pascual-Salcedo D, Plasencia C, Ramiro S, Nuño L, Bonilla G, Nagore D, Ruiz Del Agua A, Martínez A, Aarden L, Martín-Mola E, Balsa A.
    Rheumatology (Oxford); 2011 Aug 01; 50(8):1445-52. PubMed ID: 21427177
    [Abstract] [Full Text] [Related]

  • 11. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV, Alamanos Y, Nikas SN, Bougias DV, Temekonidis TI, Drosos AA.
    Am J Med; 2005 May 01; 118(5):515-20. PubMed ID: 15866254
    [Abstract] [Full Text] [Related]

  • 12. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan 01; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 13. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.
    Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G.
    Ann Rheum Dis; 2004 Oct 01; 63(10):1218-21. PubMed ID: 15361374
    [Abstract] [Full Text] [Related]

  • 14. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
    Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A.
    Clin Exp Rheumatol; 2004 Oct 01; 22(6):756-8. PubMed ID: 15638051
    [Abstract] [Full Text] [Related]

  • 15. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure.
    Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, Essioux L, Klause U.
    Rheumatology (Oxford); 2013 Jul 01; 52(7):1245-53. PubMed ID: 23459699
    [Abstract] [Full Text] [Related]

  • 16. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep 01; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 17. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment.
    Levälampi T, Korpela M, Vuolteenaho K, Moilanen E.
    Scand J Rheumatol; 2008 Sep 01; 37(1):6-12. PubMed ID: 18189188
    [Abstract] [Full Text] [Related]

  • 18. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.
    Rheumatology (Oxford); 2007 Mar 01; 46(3):446-53. PubMed ID: 16899502
    [Abstract] [Full Text] [Related]

  • 19. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
    Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, Nagaya I.
    J Rheumatol; 2006 Jan 01; 33(1):37-44. PubMed ID: 16395748
    [Abstract] [Full Text] [Related]

  • 20. The use of infliximab in academic rheumatology practice: an audit of early clinical experience.
    Fitzcharles MA, Clayton D, Ménard HA.
    J Rheumatol; 2002 Dec 01; 29(12):2525-30. PubMed ID: 12465146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.